Stoke Therapeutics Inc
STOK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.95B
Close$
$-2.95
110.1% downside
Current Fair Value
110.1% downsideOvervalued by 110.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.95 Billion |
|---|---|
| Enterprise Value | $1.81 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.18 |
| Outstanding Shares | 63,063,507 |
Return
| Return on Equity | -42.99% |
|---|---|
| Return on Assets | -38.30% |
| Return on Invested Capital | -46.03% |
Valuation & Multiples
| P/E Ratio | -11.09 |
|---|---|
| PEG | 7.68 |
| Price to Sales | - |
| Price to Book Ratio | 4.86 |
| Enterprise Value to Revenue | 56.38 |
| Enterprise Value to EBIT | -9.76 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$6.48 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$4.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 245.40% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.88%▼ 118.19% |
|---|---|
| Total Invested | $38.82M▼ 98.32% |
| Investors Holding | 7▼ 197.00% |
ESG Score
No data
About Stoke Therapeutics Inc
CEO: Edward Kaye